4Q15 US Angiomax sales by MDCO were $18.7M; however, MDCO received $29.4M from NVS for its 4Q15 profit share of NVS’ Angiomax authorized generic. MDCO is no longer promoting the branded drug.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”